Roche spending spree continues with Mirus Bio

Swiss pharmaceutical and diagnostics group Roche says it will buy the United States gene therapy company Mirus Bio Corporation for $125 million (SFr126.7 million).

This content was published on July 22, 2008 - 14:20

The announcement comes a day after Roche launched a $43.7 billion takeover bid for Genentech, the largest takeover bid by a Swiss concern.

Wisconsin-based Mirus Bio is developing RNAi, or gene silencing, a technology that uses mechanisms within the body to target and "turn off" certain genes associated with cancer and other diseases.

Roche said it would maintain an RNAi research site in the US after the takeover. The move is expected to be completed during the second half of this year, Roche said.

Last year Roche acquired rights for the gene-silencing technology of biotechnology company Alnylam Pharmaceuticals as part of a deal potentially worth $1 billion.

This article was automatically imported from our old content management system. If you see any display errors, please let us know:

In compliance with the JTI standards

In compliance with the JTI standards

More: SWI certified by the Journalism Trust Initiative

Contributions under this article have been turned off. You can find an overview of ongoing debates with our journalists here. Please join us!

If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at

Share this story

Change your password

Do you really want to delete your profile?